Navigation Links
Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
Date:12/14/2009

llion milestone payment is part of the previously announced $90 million of potential milestones which Transcept is eligible to receive upon the achievement of certain intellectual property and U.S. net sales targets.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

Forward Looking Statements

This press release contains forward looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the safe harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the ability of patents to provide important intellectual property protection for Intermezzo®; expectations with regard to Hatch-Waxman regulatory exclusivity; expectation of patent issuance and Orange Book listing after a Notice of Allowance is published by t
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... 30, 2014   Acutus Medical, Inc. ... real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping ... or sustain complex cardiac arrhythmias, including atrial fibrillation, announced ... developing its imaging/mapping system as well as bring to ... Acutus Medical to complete work on the AcQMap TM ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... 2014 EverStryke , the permanent match ... SurvivalLife.com along with a free book and class all about ... Michaels, prompting an investigative review. , “Joe Marshall of ... survival and preparation niche, and this product is an excellent ... and survival products that Joe offers on his website to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... President of ... the Lyme Disease Association., JACKSON, N.J., Oct. 4 The ... "A Clinical Appraisal,of ,Chronic Lyme Disease.," Eleven of its authors also ... by the,Connecticut Attorney General for the development of those Guidelines.,Although the ...
... to stress the disease,s link to heart disease , , THURSDAY, Oct. ... pretty. , An acclaimed rock musician and record producer, he was ... Fox television,s soon-to-be monster hit American Idol . , Then ... diabetes. , Today, with his disease under control, Jackson wants to ...
... technological know how to patient care were demonstrated by ... , Imperials Rector, Sir Richard Sykes, and Professor of ... Darzi, took the PM on a tour of the ... The Institute is at the forefront of medical innovation, ...
... Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ) ... to Chief Scientific Officer of Delivery. Dr. Costantino,will ... new,drug delivery technologies for peptide and protein therapeutics. ... is retiring,tomorrow, October 5, 2007, as was previously ...
... Oct. 4 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM: TSX-V) ... the American,College of Surgeons 93rd Annual Clinical Congress ... CRH will be focused on recruiting General ... its number of Centers for,Colorectal Health. Commenting ...
... Series, new rules for the first time forced players to ... and coaches had to strategize how pitchers were used more ... 12 and under could throw up to six innings per ... an increase in reported cases of young pitchers experiencing arm ...
Cached Medicine News:Health News:NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association 2Health News:Randy Jackson Takes Aim at Diabetes 2Health News:Randy Jackson Takes Aim at Diabetes 3Health News:Prime Minister views innovative health technology at Imperial College London 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress 2Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: